Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | FASN | P49327 | 5/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | COMT | P21964 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4565605 | 0.88 | MAPK14 (0.37) | MAPK14FASNGSK3BDDB1CRBN | |
| SCHEMBL4565609 | 0.87 | FASN (0.38) | FASNGSK3BCOMTDDB1CRBN | |
| SCHEMBL4564691 | 0.87 | FASN (0.36) | FASNGSK3BCOMTDDB1CRBN | |
| SCHEMBL4564364 | 0.85 | HTR6 (0.36) | MAPK14FASNGSK3B | |
| SCHEMBL4564893 | 0.83 | FASN (0.35) | MAPK14FASNGSK3B | |
| SCHEMBL4565737 | 0.82 | GSK3B (0.37) | MAPK14FASNGSK3BDDB1CRBN | |
| SCHEMBL4561087 | 0.82 | LOXL2 (0.33) | MAPK14FASNGSK3BDDB1CRBN | |
| SCHEMBL4564399 | 0.81 | FASN (0.37) | FASNGSK3BDDB1CRBN | |
| SCHEMBL15544262 | 0.76 | FASN (0.35) | MAPK14FASNGSK3BDDB1CRBN | |
| SCHEMBL4561931 | 0.76 | FASN (0.41) | MAPK14FASNGSK3BDDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2637660-A1 | FATTY ACID SYNTHASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012064642-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-05-18 | — | — | WO | disclosed |